Fig. 1From: Cost-effectiveness analysis of newborn screening by tandem mass spectrometry in Shenzhen, China: value and affordability of new screening technologyStates transition of IEMsa. a(i) CIT I, CIT II and HCY: Mental Retardation [49]; (ii) PKU, GA-I: Neurological Damage [53]; (iii) MCAD, PCD and VLCAD: Development Delay[47]; (iv) IVA, MMA and PA: Neurological Damage and Renal Damage [49]; (v) MSUD: Neurological Damage and Development Delay [49]Back to article page